Theralase(r) closes non-brokered private placement

Toronto, on / accesswire / november 15, 2024 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering ("offering") of units ("units"). on closing, the corporation issued an aggregate of 2,221,334 units at a price of $can 0.30 per unit for aggregate gross proceeds of approximately $can 666,400.
CAN Ratings Summary
CAN Quant Ranking